Skip to main content

Table 3 Multivariate analysis of the factors associated with the prescription of abiraterone acetate plus prednisone

From: Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO)

Factors Beta p-value OR (95% CI)
Intercept −2.713 0.109  
Age 0.057 0.015 1.06 (1.01 to 1.11)
LDH −1.120 0.009 0.33 (0.14 to 0.76)
  1. CI, confidence interval: LDH, lactate dehydrogenase; OR, odds ratio